An outpatient antibacterial stewardship intervention during the journey to JCI accreditation

Table 2 Approach of i.v. to oral antibacterial switch therapy

i.v. antibacterials	Oral antibacterials	Daily expenditure ratio (oral to i.v.)
Fluoroquinolones
i.v. moxifloxacin	Moxifloxacin tablets	0.10
i.v. levofloxacin	Levofloxacin tablets	0.13
Cephalosporins
The first generation
i.v. cefathiamidine	Cefradine capsules	0.056
i.v. cefathiamidine	The second generation cephalosporins and macrolides	0.041-0.14 (median: 0.078)
The second generation
i.v. cefotiam	Cefaclor capsules	0.092
i.v. cefuroxime sodium	Cefaclor SR tablets	0.99
	Cefprozi tablets	0.15
	Cefuroxime axetil tablets	0.061
The third generation
i.v. ceftizoxime sodium	Cefdinir capsules	0.35
i.v. ceftriaxone sodium	Cefetamet pivoxil tablets	0.042
Macrolides
i.v. azithromycin	Azithromycin tablets	0.29
	Roxithromycin tablets	0.13
	Clarithromycin SR tablets	0.088
	Clarithromycin tablets	0.21
Aminoglycosides
i.v. etimicin	Levofloxacin tablets	0.097
	Cefdinir capsules	0.34
	Cefetamet pivoxil tablets	0.090
Nitroimidazoles
i.v. ornidazole	Ornidazole tablets	0.017
Lincosamide
i.v. clindamycin	Clindamycin palmitate tablets	1.11

Daily expenditure was expressed in Chinese Yuan Renminbi (CNY); i.v.: intravenous; SR: sustained release. Daily expenditure ratio (oral to i.v.) was calculated as daily expenditure of oral antibacterial divided by daily expenditure of the corresponding i.v. antibacterial.

ISSN: 2050-6511